The challenge of CMC regulatory compliance for biopharmaceuticals

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

Volumn , Issue , 2019, Pages 1-426

  Geigert, John ^a  

^a BioPharmaceutical Quality Solutions   (United States)

Author keywords

Atmps Advanced Therapy Medicinal Products; Biosimilars; Biotech Drugs; Cgt Cell And Gene Therpy Products; F I H Studies; Living Genetically Engineered Viruses; Monoclonal Antibodies; Pharmaceutical Qa Qc; Prime Priority Medicines; Recombinant Protein; Risk Based Clinical Development; Rmat Regenerative Medicines Advanced Therapy

Indexed keywords

EID: 85098461365     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-030-13754-0     Document Type: Book

References (347)

1. FDA 101: Biological Products; FDA website, www.fda.gov/forconsumers/consumerupdates/ucm048341.htm
2. EMA News (15/08/2016): Better Monitoring of Biological Medicines – New Chapterin Guidelines on Good Pharmacoviligence Practices; www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/08/news_detail_002590.jsp
3. Health Canada: Abbreviations/Definitions; Health Canada website, www.canada.ca/en/healthcanada/services/drugs-health-products/drug-products/applications-submissions/guidancedocuments/clinical-trials/abbreviations-definitions.html
4. FDA Center for Biologics Evaluation and Research History: 100 Year of Biologics Regulation(2002); www.fda.gov/aboutFDA/history/forgshistory/historyoffdascentersandoffices/ucm2017807.htm
5. Center for Disease Control and Prevention (CDC) Measles History; CDC website, www.cdc.gov/measles/about/history.html
6. FDA Vaccines, Blood & Biologics: Approved Vaccine Products; FDA website, www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/default.htm
7. FDA Center for Biologics Evaluation and Research History: Science and the Regulation ofBiological Products Preface (2002); www.fda.gov/aboutfda/history/forgshistory/historyoffdascentersandoffices/ucm2017807.htm
8. FDA Vaccines, Blood & Biologics: Fractionated Plasma Products; FDA website, www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/default.htm
9. FDA: Historical Case Studies of Drug Regulation : Celebrating a Milestone – FDA’s Approvalof the First Genetically-Engineered Product (2007); www.fda.gov/AboutFDA/History/ProductRegulation/ucm593465.htm
10. Pharmaceutical Research and Manufacturers of America (PhRMA) website; www.phrma.org
11. ICH S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1)(June 2011); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf
12. Urquhart, L., Market Watch: Top Drugs and Companies By Sales in 2017; Nature ReviewsDrug Discovery17, 232(April2018); www.nature.com/articles/nrd.2018.42
13. FDA Drugs: Biosimilars; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm
14. EMA Human Regulatory: Biosimilars; EMA website, www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp
15. Health Canada Drugs and Health Products: Biosimilar Biologic Drugs; Health Canada website,www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/biosimilar-biologic-drugs.html
16. WHO Biologicals: Similar Biotherapeutic Products; WHO website, www.who.int/biologicals/biotherapeutics/similar_biotherapeutic_products/en
17. FDA Drugs – Biosimilar Product Information: FDA-Approved Biosimilar Products; FDA website,www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580432.htm
18. EMA Human Medicines – Find Medicine: European Public Assessment Reports – Browse byType; EMA website, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp
19. FDA Vaccines, Blood & Biologics: Cellular and Gene Therapy Products; FDA website, www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm
20. EMA Human Regulatory: Advanced Therapies; EMA website, www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000294.jsp
21. FDA Vaccines, Blood & Biologics: Cellular and Gene Therapy Products – Regenerative MedicineAdvanced Therapy Designation; FDA website, www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm
22. FDA Vaccines, Blood Products & Biologics: Approved Products – Provenge (Sipuleucel) –FDA Package Insert and Patient Information (2010); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf
23. EMA European Public Assessment Report: Imlygic (Talimogene Laherparepvec) (2015);www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002771/WC500201082.pdf
24. Kymriah (Tisagenlecleucel) FDA Briefing Document Oncologic Drugs AdvisoryCommittee Meeting July 12, 2017; www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf
25. EMA Advanced Therapy Classification: Summaries of Scientific Recommendations onClassification of Advanced Therapy Medicinal Products; EMA website, www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000301.jsp
26. EMA PRIME – Priority Medicines: A Two-year Overview, EMA/242980/2018; EMA website,www.ema.europa.eu/docs/en_GB/document_library/Report/2018/05/WC500248828.pdf
27. FDA – Speeches by FDA Officials: Remarks by Commissioner Gottlieb to the Alliance forRegenerative Medicine’s Annual Board Meeting (May 22, 2018); www.fda.gov/NewsEvents/Speeches/ucm609579.htm
28. FDA CFR Code of Federal Regulations: Title 21 Part 312 Investigational New Drug Application;FDA website, www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=312
29. FDA Code of Federal Regulations: Title 21 Part 314 Applications for FDA Approval to Marketa New Drug; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=314
30. FDA Draft Guidance for Industry: Determining Whether to Submit an ANDAor a 505(b)(2) Application (October 2017); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM579751.pdf
31. FDA Drug Safety and Availability: Generic Enoxaparin Questions and Answers; www.fda.gov/Drugs/DrugSafety/ucm220037.htm
32. FDA Code of Federal Regulations: Title 21 Part 600–680 Subchapter F – Biologics; eCFRwebsite, www.ecfr.gov/cgi-bin/text-idx?SID=e9030f5ed5963eb10787bbc88fcd8d28&mc=true&tpl=/ecfrbrowse/Title21/21cfrv7_02.tpl#0
33. United States Congress 262: Regulation of Biological Products (June 2018); uscode.house.gov/view.xhtml?req=(title:42%20section:262%20edition:prelim)
34. FDA Guidance For Industry Biosimilars: Questions and Answers Regarding Implementationof the Biologics Price Competition and Innovation Act of 2009 (April 2015); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM273001.pdf
35. Pharmaceutical Research and Manufacturers of America (PhRMA), April 16, 2012, WrittenResponse to Docket No. FDA-2011-D-0602: Draft Guidance for Industry on QualityConsiderations in Demonstrating Biosimilarity to a Reference Protein Product; 77 Fed. Reg.8884 (Feb. 15, 2012); www.pharmamedtechbi.com/~/media/Supporting%20Documents/The%20Pink%20Sheet/74/17/PhRMAqualityconsiderations.pdf
36. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products; FDA website, www.accessdata.fda.gov/scripts/cder/daf/index.cfm
37. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products – Mylotarg (GemtuzumabOxogamicin) – Market Approval Letter (2017); www.accessdata.fda.gov/scripts/cder/daf/index.cfm
38. FDA Guidance for Industry (Draft): Implementation of the “Deemed to be a License” Provisionof the Biologics Price Competition and Innovation Act of 2009 (March 2016); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM490264.pdf
39. US Federal Register Vol 77 Docket No. FDA-2012-N-0080 Amendments to SterilityTest Requirements For Biological Products, Effective June 04, 2012, pp 26162–26175 (May 03, 2012); www.federalregister.gov/articles/2012/05/03/2012-10649/amendments-to-sterility-test-requirements-for-biological-products
40. US Federal Register Vol 80 Docket No. FDA-2015-N-1110 Revocation of General SafetyRegulations That Are Duplicative of Requirements in Biologics License Applications,Effective August 03, 2015, pp 37971–37974 (July 02, 2015); www.federalregister.gov/documents/2015/07/02/2015-16366/revocation-of-general-safety-test-regulations-that-are-duplicative-of-requirements-in-biologics
41. FDA CFR Code of Federal Regulations: Title 21, Part 610.14 Identity; www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol7/pdf/CFR-2011-title21-vol7-part610.pdf
42. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products – Trogarzo (Ibalizumab-uiyk)– Approval History, Letters, Reviews and Related Documents – Administrative andCorrespondence Documents – Meeting Minutes Mid-Cycle Communication (August 18,2017); www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761065Orig1s000AdminCorres.pdf
43. FDA Celltrion Establishment Inspection Report (June 2017); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM603271.pdf
44. FDA Code of Federal Regulations Title 21 Food and Drugs – Part 610.2 Request For Samplesand Protocols, Official Release; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=610.2
45. FDA Vaccines, Blood & Biologics: Influenza Virus Vaccine Composition and Lot Release; FDAwebsite, www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm062928.htm
46. FDA Vaccines, Blood & Biologics: Approved Products – Shingrix (Zoster VaccineRecombinant, Adjuvanted) – Approval Letter (October 20, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM581750.pdf
47. FDA Vaccines, Blood & Biologics: Approved Products – Bexsero (Meningococcal GroupB Vaccine) – Approval Letter (January 23, 2015); www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm431446.htm
48. FDA Vaccines, Blood & Biologics: Approved Products – Fibryna (HumanFibrinogen) – Approval Letter (June 07, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM562369.pdf
49. FDA Vaccines, Blood & Biologics: Approved Products – Heplisav-B (Hepatitis B Vaccine,Recombinant, Adjuvanted) – Approval Letter (November 09, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM584820.pdf
50. FDA Vaccines, Blood & Biologics: Approved Products – Rebinyn (Coagulation Factor IX,Recombinant, GlycoPEGylated – Approval Letter (May 31, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM561415.pdf
51. US Federal Register Vol 60 Docket No. FDA-95 N–0371 Interim Definition and Eliminationof Lot-by-Lot Release for Well-Characterized Therapeutic Recombinant DNA-Derived andMonoclonal Antibody Biotechnology Products (December 08, 1995); www.gpo.gov/fdsys/pkg/FR-1995-12-08/pdf/95-29960.pdf
52. Code of Federal Regulations Title 21 Food and Drugs – Part 601.2 Applications for BiologicsLicenses; www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol7/pdf/CFR-2011-title21-vol7-part601.pdf
53. FDA Drugs Database: Drugs@FDA – FDA Approved Drug Products – Fulphila (Pegfilgrastim-jmdb)– Approval Letter (June 04, 2018); www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761075Orig1s000Ltr.pdf
54. FDA Drugs Database: Drugs@FDA – FDA Approved Drug Products – Crysvita (Burosumab-twza)– Approval Letter (April 17, 2018); www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761068Orig1s000ltr.pdf
55. FDA Vaccines, Blood & Biologics: Approved Products – Imlygic (TalimogeneLaherparepvec) – Approval Letter (October 27, 2015); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469670.pdf
56. FDA Vaccines, Blood & Biologics: Approved Products – Luxturna (Voretigene Neparvovecrzyl)– Approval Letter (December 19, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM589690.pdf
57. FDA Vaccines, Blood & Biologics: Approved Products – Kymriah (Tisagenlecleucel) –Approval Letter (August 30, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM574106.pdf
58. FDA Vaccines, Blood & Biologics: Approved Products – Yescarta (Axicabtagene Ciloleucel) –Approval Letter (October 18, 2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581259.pdf
59. Code of Federal Regulations Title 21 Food and Drugs – Part 600.14 Reporting of BiologicalProduct Deviations By Licensed Manufacturers; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=600.14
60. Code of Federal Regulations Title 21 Food and Drugs – Part 314.81 Other PostmarketingReports; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=314.81
61. FDA Inspections, Compliance, Enforcement, and Criminal Investigations – RegulatoryProcedures Manual: Injunctions; FDA website, www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm176734.htm
62. Code of Federal Regulations Title 21 Food and Drugs – Part 601.6 Suspension of License;www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart=601.6
63. FDA Frequently Asked Questions About Therapeutic Biological Products; FDA website,www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm
64. FDA Transfer of Therapeutic Products to the Center for Drug Evaluation and Research; FDAwebsite, www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133463.htm
65. FDA Warning Letter Issued to Amgen (January 27, 2014); FDA Warning Letters website,www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm385288.htm
66. FDA Search for FDA Guidance Documents: Combination Products Guidance Documents;FDA website, www.fda.gov/RegulatoryInformation/Guidances/ucm122047.htm
67. EC Directive 2001/83/EC of the European Parliament and Council, Concerning CommunityCode Relating to Medicinal Products for Human Use; ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_cons2009/2001_83_cons2009_en.pdf
68. EC Directive 2001/20/EC of the European Parliament and Council, Concerning Implementationof Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for HumanUse; ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf
69. EC Detailed Guidance for the Request of Authorisation of a Clinical Trial on a MedicinalProduct for Human Use to the Competent Authorities, Notification of Substantial Amendmentsand Declaration of the End of the Trial (March 2010); ec.europa.eu/health/files/eudralex/vol-10/2010_c82_01/2010_c82_01_en.pdf
70. Heads of Medicines Agencies: Clinical Trials Facilitation Group – GuidanceDocument for a Voluntary Harmonisation Procedure (VHP) For the Assessmentof Multinational Clinical Trial Applications, Version 2 (March 2010); http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2010_03_VHP_Guidance_v2.pdf
71. EC Medicinal Products – Clinical Trials: Regulation 536/2014; ec.europa.eu/health/human-use/clinical-trials/regulation_en
72. EC Medicinal Products – Authorisation and Supervision of Medicinal Products: Regulation726/2004; ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf
73. FDA Drugs Database: Search Drugs@FDA – FDA Approved Drug Products – Crysvita(Burosumab-twza) – Approval Letter (April 17, 2018); www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761068Orig1s000ltr.pdf
74. FDA Vaccines, Blood and Biologics – Approved Products: Afluria (Influenze Virus Vaccine) –Approval Letter (September 28, 2007); wayback.archive-it.org/7993/20170723030201/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm177457.htm
75. ICH Members and Observers (November 2018); www.ICH.org/about/members-observers.html
76. FDA Drugs Database: Search Drugs@FDA – FDA Approved Drug Products – Trogarzo(Ibalizumab-uiyk) – Approval Letter (March 6, 2018); www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761065Orig1s000ltr.pdf
77. EMA European Public Assessment Report (EPAR): Grastofil (Recombinant Human Filgrastim)Biosimilar (July 2013); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002150/WC500154066.pdf
78. FDA Drugs Database: Search Drugs@FDA – FDA Approved Drug Products – Ogivri(Trastuzumab-dkst) Biosimilar – Approval Letter (December 1, 2017); www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761074Orig1s000ltr.pdf
79. EMA European Public Assessment Report (EPAR): Inflectra (Infliximab) Biosimilar (June2013); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf
80. FDA Drugs Database: Search Drugs@FDA – FDA Approved Drug Products – Inflectra(Infliximab-dyyb) Biosimilar – Approval Letter (April 5, 2016); www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/125544Orig1s000ltr.pdf
81. Samsung BioLogics website: www.samsungbiologics.com/front/eng/main.do
82. FDA About the Center for Biologics Evaluation and Research: What Are “Biologics –Questions and Answers; FDA website, www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133077.htm
83. FDA Drugs: Frequently Asked Questions About Therapeutic Biological Products; FDA website,www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm
84. EMA Biosimilars in the EU: Information Guide for Healthcare Workers (April 2017); www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
85. EU EudraLex The Rules Governing Medicinal Products in the European Union, Volume4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human andVeterinary Use, Annex 2 Manufacture of Biological Medicinal Substances and Productsfor Human Use (June 2018); ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/pdfs-en/2018_annex2_en.pdf
86. ICH Q6A Specifications: Test Procedures and Acceptance Criteria For New Drug Substancesand New Drug Products: Chemical Substances (October 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6A/Step4/Q6Astep4.pdf
87. ICH Q6B Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
88. ICH Q1A(R2) Stability Testing of New Drug Substances and New Drug Products (February2003); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf
89. ICH Q5C Stability Testing of Biotechnological/Biological Products (November 1995);ICH website, www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.pdf
90. ICH Q5A(R1) Viral Safety Evaluation of Biotechnology Products Derived From Cell Linesof Human or Animal Origin (September 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1__Guideline.pdf
91. FDA Generic Drugs: What is the Approval Process for Generic Drugs; FDA website, www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/ucm506040.htm
92. FDA CPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act(May 1992); www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-ice/documents/webcontent/ucm074367.pdf
93. Council of Europe: European Pharmacopeia (Ph.Eur.) – Background & Mission; EDQMwebsite, www.edqm.eu/en/european-pharmacopoeia-background-50.html
94. FDA Letter to USP: Drug Product Monographs for Biological Products (March 28,2018); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM602973.pdf
95. ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in TheirManufacturing Process (November 2004); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf
96. FDA Biotechnology Inspection Guide (November 1991); www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074181.htm
97. Schiestl, M., Stangler, T., et al., Acceptable Changes in Quality Attributes of Glycosylated Biopharmaceuticals; Nat Biotechol(2011)29: 310–312
98. FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of aTherapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/drugs/guidances/ucm291134.pdf
99. Deller, M.C., Kong, L, and RuppB., Protein Stability: A Crystallographer’s Perspective; ActaCryst. (2016)F72: 72–95; www.ncbi.nlm.nih.gov/pmc/articles/PMC4741188/
100. FDA Guidance for Industry: Characterization and Qualification of Cell Substrates and OtherBiological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications(February 2010); www.fda.gov/downloads/BiologicsBloodVaccines/UCM202439.pdf
101. FDA Guidance for Industry: Considerations for the Design of Early-Phase ClinicalTrials of Cellular and Gene Therapy Products (June 2015); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM564952.pdf
102. FDA Vaccines, Blood & Biologics: Biologics Research Projects – Evaluation of Safety andPotency of Viral Vaccines Based on Analysis of Molecular Consistency; FDA website, www.fda.gov/BiologicsBloodVaccines/ScienceResearch/BiologicsResearchAreas/ucm127312.htm
103. EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene TherapyMedicinal Products (March 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf
104. EMA/EC: Biosimilars in th EU – Information Guide for Healthcare Professionals (2017);www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
105. Kozlowski, S. and Swann, P., Current and Future Issues in the Manufacturing and Development of Monoclonal Antibodies; Adv. Drug Deliv Rev. (2006Aug 7)58(5–6): 707–722
106. EMA Guideline on Immunogenicity Assessment of Therapeutic Proteins (May 2017);www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/06/WC500228861.pdf
107. EMA European Public Assessment Report (EPAR): Glybera (Alipogene Tiparvovec) (July2012); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002145/WC500135476.pdf
108. FDA – Speeches by FDA Officials: Remarks by Commissioner Gottlieb to the Alliance forRegenerative Medicine’s Annual Board Meeting (May 22, 2018); www.fda.gov/NewsEvents/Speeches/ucm609579.htm
109. FDA Drugs – Therapeutic Biological Applications (BLA): Biosimilars –Biosimilar and Interchangeable Products; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm
110. EMA/EC What I Need to Know About Biosimilar Meedicines – Information for Patients (2017);ec.europa.eu/growth/content/information-patients-what-i-need-know-about-biosimilarmedicines-0_en
111. Health Canada Biologics, Radiopharmaceuticals and Generic Therapies: Fact Sheet -Biosimilars; HC website, www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html
112. World Health Organization Biologicals – Similar Biotherapeutic Products: Annex 2 –Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) – Technical ReportSeries No. 977 (2013); www.who.int/biologicals/publications/trs/areas/biological_therapeutics/TRS_977_Annex_2.pdf?ua=1
113. FDA Drugs – Therapeutic Biological Applications (BLA): Biosimilars – BiosimilarDevelopment, Review and Approval; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580429.htm
114. FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of aTherapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf
115. EMA Procedural Advice for Users of the Centralised Procedure for Similar BiologicalMedicinal Products Applications (May 2017); www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf
116. World Health Organization Expert Committee on Biological Standardization: Guidelines onEvaluation of Similar Biotherapeutic Products (SBPs) (2009); www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
117. FDA Drugs -Therapeutic Biologic Applications (BLA): Biosimilar and InterchangeableProducts; FDA website, www.fda.gov/Drugs/DevelopmentApprovalProcess/H o w D r u g s a r e D e v e l o p e d a n d A p p r o v e d / A p p r o v a l A p p l i c a t i o n s /TherapeuticBiologicApplications/Biosimilars/ucm580419.htm#biosimilar
118. EMA/EC Biosimilars in the EU: Information guide for healthcare professionals (2017); www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
119. FDA Draft Guidance for Industry: Considerations in Demonstrating Interchangeabilitywith a Reference Product (January 2017); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf
120. WHO Essential Medicines and Health Products: International Nonproprietary Names; WHOwebsite, www.who.int/medicines/services/inn/en/
121. FDA Guidance for Industry: Nonproprietary Naming of Biological Products (January 2017);www.fda.gov/downloads/drugs/guidances/ucm459987.pdf
122. WHO Essential Medicines and Health Products: Biological Qualifier; WHO website, www.who.int/medicines/services/inn/inn_bio_bq/en/
123. ICH Q10 Pharmaceutical Quality System (June 2008); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf
124. FDA Guidance For Industry – Contract Manufacturing Arrangements for Drugs: QualityAgreements (November 2016); www.fda.gov/downloads/drugs/guidances/ucm353925.pdf
125. FDA Drugs: Form 483 – Biocon Limited May 25, 2017 – June 3, 2017; www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM569851.pdf
126. FDA Inspections, Compliance, Enforcement, and Criminal Investigations : WarningLetters – Celltrion Inc. January 26,2 018 – Warning Letter 320–18-28; www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm594395.htm
127. CMC Biotech Working Group – A-Mab: A Case Study in Bioprocess Development (October30, 2009); CASSS website, cdn.ymaws.com/www.casss.org/resource/resmgr/imported/AMab_Case_Study_Version_2-1.pdf
128. FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meeting: Sparks TherapyBriefing Document (October 12, 2017) – Luxturna (Voretigene neparvovec); www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/cellulartissueandgenetherapiesadvisorycommittee/ucm579300.pdf
129. FDA Consumer Updates: Creating Human Drugs From Genetically Engineered Animals;FDA website, www.fda.gov/ForConsumers/ConsumerUpdates/ucm143980.htm
130. FDA Vaccines, Blood & Biologics: Cellular & Gene Therapy Products – What is GeneTherapy; FDA website, www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm573960.htm
131. EMA Guideline on Immunogenicity Assessment of Therapeutic Proteins (May 2017);www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/06/WC500228861.pdf
132. EMA Guideline on the Quality of Biologically Active Substances Produced by StableTransgene Expression in Higher Plants (July 2008); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003154.pdf
133. EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene TherapyMedicinal Products (March 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf
134. A-VAX: Applying Quality By Design to Vaccines – CMC-Vaccines Working Group (May2012); www.dcvmn.org/IMG/pdf/a-vax-applying-qbd-to-vaccines_2012.pdf
135. ICH Q11 Development and Manufacture of Drug Substances (Chemical Entities andBiotechnological/Biological Entities) (May 2012); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf
136. EMA European Public Assessment Report (EPAR): Perjeta (Pertuzumab) (December 2012);www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002547/WC500141004.pdf
137. Alt, N., Zhang, T.Y. et.al., Determination of Critical Quality Attributes For Monoclonal Antibodies Using Quality by Design Principles, Biologicals(2016)44: 291–305
138. Hakemeyer, C., McKnight, N., et.al., Process Characterization and Design Space Definition,Biologicals(2016)44: 306–318
139. EMA European Public Assessment Report (EPAR): Prolia (Denosumab) (March 2010);www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001120/WC500093529.pdf
140. FDA Vaccines, Blood & Biologics: Licensed Products with Supporting Data –Rixubis (Coagulation Factor IX, Recombinant) – Approval History, Letters,Reviews, and Related Documents – Final CMC Review (April 2013); www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm358781.htm
141. Kepert, J.F., Cromwell, M., et. al., Establishing a Control System Using QbD Principles,Biologicals(2016)44: 319–331
142. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products – Gazyva (Obinutuzumab)(November 2013); www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125486Orig1s000ltr.pdf
143. EMA European Public Assessment Report (EPAR): Gazyvaro (Obinutuzumab) (May 2014);www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002799/WC500171596.pdf
144. FDA CDER Manual of Policies & Procedures (MAPP): 5016.1 Applying ICH Q8(R2), Q9and Q10 Principles to CMC Review (May 2016); www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/default.htm
145. EMA European Public Assessment Report (EPAR): Oxervate (Cenegermin) (May 2017) ;www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004209/WC500232107.pdf
146. EMA European Public Assessment Report (EPAR): Brineura (Cerliponase Alfa) (April 2017); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004065/WC500229800.pdf
147. EMA European Public Assessment Report (EPAR): Hemlibra (Emicizumab) (January 2018); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004406/WC500244745.pdf
148. EMA European Public Assessment Report (EPAR): Shingrix (Herpes Zoster Vaccine,Recombinant, Adjunvanted) (January 2018); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004336/WC500246552.pdf
149. EMA European Public Assessment Report (EPAR): Coagadex (Human Coagulation Factor X)(January 2016) ; www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003855/WC500204191.pdf
150. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Luxturna (Voretigene Neparvovec-rzyl) – Approval History, Letters, Reviews, and RelatedDocuments – CMC Review (December 2017); www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm589507.htm
151. EMA European Public Assessment Report (EPAR): Zalmoxis (Allogeneic T-Cells GeneticallyModified with a Retroviral Vector Encoding for a Truncated Form of the Human Low AffinityNerve Growth Factor Receptor (ΔLNGFR) and the Herpes Simplex I Virus Thymidine Kinase(HSV-TK Mut2)) (June 2016); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002801/WC500212588.pdf
152. EMA European Public Assessment Report (EPAR) – Withdrawn Applications: Ixinity(Recombinant Coagulation Factor IX) (September 2012) ; www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2013/09/WC500149845.pdf
153. FDA Code of Federal Regulations (CFR) Title 21 Part 312.23 – General Principles ofthe IND Submission; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=312
154. FDA Guidance for Industry: CGMP for Phase 1 Investigational Drugs (2008); www.fda.gov/downloads/drugs/guidances/ucm070273.pdf
155. FDA (Draft) Guidance Industry: Chemistry, Manufacturing, and Control (CMC) Informationfor Human Gene Therapy Investigational New Drug Applications (INDs) (July 2018); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610795.pdf
156. EMA Guideline on the Requirements for Quality Documentation Concerning BiologicalInvestigational Medicinal Products in Clinical Trials (September 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-requirements-quality-documentation-concerningbiological-investigational-medicinal_en-0.pdf
157. European Commission – EudraLex the Rules Governing Medicinal Products in the EuropeanUnion, Volume 4, Good Manufacturing Practice: Guidelines on Good Manufacturing PracticeSpecific to Advanced Therapy Medicinal Products (November 2017); ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
158. Parenteral Drug Association (PDA) Technical Report No. 56 (Revised 2016): Application ofPhase-Appropriate Quality System and cGMP to the Development of Therapeutic ProteinDrug Substance (API or Biologic Active Substance); PDA website, www.PDA.org
159. Parenteral Drug Association (PDA) Technical Report (2019): Cell-Based Therapy ControlStrategy; PDA website, www.PDA.org
160. EMA Workshop on the Guideline for First-in-Man Clinical Trials For Potentially High-RiskMedicinal Products: TGN 1412 – What Really Happened?; EMA website, www.ema.europa.eu/docs/en_GB/document_library/Presentation/2009/11/WC500010858.pdf
161. National Institutes of Health (NIH) News Release: NIH Suspends Operations in its ClinicalCenter Pharmaceutical Development Section (June 4, 2015) – FDA Form 483; NIH website,www.cc.nih.gov/phar/pdfs/483.pdf
162. National Institutes of Health (NIH) News Release: Statement on Review of NIH SterileProduction Facilities (April 19, 2016); NIH website, www.nih.gov/news-events/news-releases/statement-review-nih-sterile-production-facilities
163. FDA Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics(May 2014); www.fda.gov/downloads/Drugs/Guidances/UCM358301.pdf
164. FDA Drug Databases: Drugs@FDA – FDA Approved Drug Products – Darzalex(Daratumumab) – CDER Memorandum of Meeting Minutes – Breakthrough TherapyDaratumumab (Janssen Biotech) (July 31, 2013); www.accessdata.fda.gov/drugsatfda_docs/nda/2015/761036Orig1s000Admincorres.pdf
165. EMA European Medicines Agency Guidance on Interactions in the Context of PRIME(May 2018); www.ema.europa.eu/docs/en_GB/document_library/Other/2018/05/WC500248826.pdf
166. FDA Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to aReference Product (April 2015); www.fda.gov/downloads/drugs/guidances/ucm291128.pdf
167. FDA Speeches by FDA Officials: Remarks by Commissioner Gottlieb to the Alliance forRegenerative Medicine’s Annual Board Meeting (May 22, 2018); www.fda.gov/NewsEvents/Speeches/ucm608445.htm
168. World Health Organization (WHO) Regulatory Risk Assessment in the Case of AdventitiousAgent Finding in a Marketed Vaccine: Scientific Principles to Consider (2013); www.who.int/biologicals/WHO_Risk_Assessment_1st_public_consultation_12_March_2013.pdf
169. ICH Q9 Quality Risk Management (November 2005); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf
170. Centers for Disease Control and Prevention (CDC): Prion Diseases; CDC website, www.cdc.gov/prions/index.html
171. Wickner, R.B., Yeast and Fungal Proteins, Cold Spring Harb Perspect Biol (2016); pdfs.semanticscholar.org/550a/dcd7c90ba03f47b05b6d108ed0eb879fa565.pdf
172. FDA Drugs: Celebrating a Milestone: FDA’s Approval of First Genetically-Engineered Product(2007); www.fda.gov/downloads/aboutfda/history/productregulation/ucm593496.pdf
173. FDA Drugs – Search Drugs@FDA: FDA Approved Drug Products – Eylea (Aflibercept):Approval History, Letters, Reviews and Related Documents – Administrative andCorrespondence Documents – Pre-BLA Meeting (September 27, 2010); www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387Orig1s000Admincorres.pdf
174. FDA Drugs – Search Drugs@FDA: FDA Approved Drug Products – Adcetris (BrentuximabVedotin): Approval History, Letters, Reviews and Related Documents – Administrative andCorrespondence Documents – Pre-BLA Meeting (December 07, 2010); www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000AdminCorres.pdf
175. FDA Drugs – Search Drugs@FDA: FDA Approved Drug Products – Blincyto (Blinatumomab):Approval History, Letters, Reviews and Related Documents – Administrative andCorrespondence Documents – Pre-BLA Meeting (April 09, 2014); www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125557Orig1s000AdminCorres.pdf
176. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with SupportingDocuments – Kymriah (Tisagenlecleucel) – Package Insert (2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf
177. European Commission (EC) Volume 4 Good Manufacturing Practice: Guidelines to GoodManufacturing Practice Specific to Advanced Therapy Medicinal Products (Novembber2017); ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
178. EMA Press Release: European Medicines Agency Confirms Positive Benefit-Risk Balanceof MabThera – Batches Produced at the Vacaville Manufacturing Site Do Not Pose Riskto Public Health, (May 2012); www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/05/WC500127776.pdf
179. Chen, J., Bergevin, J., et. al, Case Study: A Novel Bacterial Contamination in Cell Culture Production – Leptospira Licerasiae; PDA website, PDA J Pharm Sci and Tech. (2012), 66:580–591
180. FDA Drugs – Guidance, Compliance & Regulatory Information: Questions and Answerson Current Good Manufacturing Practices—Production and Process Controls –
181. CanLeptospira Species Penetrate Sterilizing-grade Filters?; FDA website, www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm124782.htm#14.
182. ICH Q11 Development and Manufacture of Drug Substances (Chemical Entities andBiotechnological/Biological Entities) (May 2012); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf
183. EC Directive 2001/83/EC of the European Parliament and Council, Concerning CommunityCode Relating to Medicinal Products for Human Use (October 2012); ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf
184. FDA Draft Guidance for Industry: Chemistry, Manufacturing, and Control (CMC) Informationfor Human Gene Therapy Investigational New Drug Applications (INDs) (July2018); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610795.pdf
185. FDA Guidance for Industry: Characterization and Qualification of Cell Substrates andOther Biological Materials Used in the Production of Viral Vaccines for InfectiousDisease Indications (February 2010); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM202439.pdf
186. EMA European Public Assessment Report (EPAR): Vimizim (Elosulfase Alfa) (February2014); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002779/WC500169242.pdf
187. EMA European Public Assessment Report (EPAR): Tecentriq (Atezolizumab) (July 2017);www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004143/WC500235780.pdf
188. EMA European Public Assessment Report (EPAR): Blincyto (Blinatumomab) (September2015); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003731/WC500198227.pdf
189. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Imlygic (Talimogene Laherparepvec) – Package Insert (2015); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf
190. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Luxturna (Voretigene Neparvovec-rzyl) – Package Insert (2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM589541.pdf
191. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Luxturna (Voretigene Neparvovec-rzyl) – Approval History, Letters, Reviews, and RelatedDocuments – CMC Review (December 8, 2017); www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm589507.htm
192. FDA Advisory Committee Meetings – Meeting of the Cellular, Tissue, and GeneTherapies Advisory Committee: Novartis Pharmaceuticals, Kymriah (Tisagenlecleucel) –FDA Advisory Committee Briefing Document Prepared by the FDA (July 12, 2017);www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf
193. EMA European Public Assessment Report (EPAR): Imlygic (Talimogene Laherparepvec)(October 2015); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002771/WC500201082.pdf
194. EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy MedicinalProducts (March 2018); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252056.pdf
195. EMA European Public Assessment Report (EPAR): Glybera (Alipogene Tiparvovec) (July2012); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002145/WC500135476.pdf
196. FDA Inspections, Compliance, Enforcement and Criminal Investigations – Warning Letters:Warning Letter to Sanofi Pasteur, July 12, 2012; wayback.archive-it.org/7993/20161023095754/http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm312929.htm
197. EMA European Public Assessment Report (EPAR): Semglee (Insulin Glargine, Biosimilarto Lantus) (January 2018); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004280/WC500249349.pdf
198. EMA European Public Assessment Report (EPAR): Abasria (Insulin Glargine) (June 2014);www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002835/WC500175383.pdf
199. EMA European Public Assessment Report (EPAR): Inflixabi (Infliximab, Biosimilarto Remicade) (April 2016); www.ema.europa.eu/documents/assessment-report/flixabi-epar-public-assessment-report_en.pdf
200. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Flublok (Seasonal FluVaccine) – Package Insert (March 2017); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM336020.pdf
201. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Cervarix (HumanPapillomavirus Recombinant Vaccine) – Package Insert (2009); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
202. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Elelyso (TaligluceraseAlfa) – Package Insert (2016); www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
203. Sarepta Therapeutics, Press Release – Sarepta Therapeutics Announces that Phase 1/2aDuchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed onClinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events(May 25, 2018); Sarepta Therapeutics website – News Releases, www.sarepta.com
204. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Kymriah(Tisagenlecleucel) – Package Insert (2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf
205. Baaj, A., Kaitin, K. I. and Serebrox, M., Manufacturing Strategy for Diverse Biologic Pipelines of the Future, Tuft Center for Study of Drug Development (October 2017); static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5aa2ff8953450a815ebf3377/1520631693367/Manufacturing-WP-2017.pdf
206. EMA European Public Assessment Report (EPAR): Adynovi (Rurioctocog Alfa Pegol)(November 2017); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004195/WC500243897.pdf
207. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Rebinyn (Recombinant Coagulation Factor IX, GlycoPEGylated) – Package Insert (June 2017);www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM561316.pdf
208. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Palynziq (Pegvaliase-pqpz) – Package Insert (May 2018); www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf
209. Kirschner, S., Associate Chief, FDA Office of Biotech Products – Immunology and ProteinTherapeutics Lab, Ask the Regulatory Session, American Association of PharmaceuticalScientists (AAPS) National Biotech Conference, May 2012, as stated in the InternationalPharmaceutical Quality (IPQ) Newsletter (June2012); www.IPQpubs.com
210. FDA Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products(August 2014); https://www.fda.gov/downloads/drugs/guidances/ucm338856.pdf
211. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Myotarg (GemtuzumabOzogamicin): Approval History, Letters, Reviews and Related Documents – Package Insert(April 2018); www.accessdata.fda.gov/drugsatfda_docs/label/2018/761060s001lbl.pdf
212. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Adcetris (BentuximabVedotin): Approval History, Letters, Reviews and Related Documents – Package Insert (March2018); www.accessdata.fda.gov/drugsatfda_docs/label/2018/125388s097lbl.pdf
213. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Besponsa (InotuzumabOzogamicin): Approval History, Letters, Reviews and Related Documents – Package Insert(August 2017); www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf
214. FDA Guidance For Industry: Sterile Drug Products Produced by Aseptic Processing –Current Good Manufacturing Practice (September 2004); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070342.pdf
215. EU EudraLex The Rules Governing Medicinal Products in the European Union, Volume4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human andVeterinary Use – Annex 1: Manufacture of Sterile Medicinal Products (November 2008); ec.europa.eu/health/files/eudralex/vol-4/2008_11_25_gmp-an1_en.pdf
216. PDA Points to Consider for Aseptic Processing, Part 1 (January 2015); PDA website, www.PDA.org
217. Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme(PIC/S): Recommendation on the Validation of Aseptic Processing (January 2011); PIC/Swebsite, picscheme.org/en/publications
218. PDA Points to Consider for Aseptic Processing, Part 2 (May 2016); PDA website, www.PDA.org
219. European Commission – EudraLex the Rules Governing Medicinal Products in the EuropeanUnion, Volume 4, Good Manufacturing Practice: Guidelines on Good Manufacturing PracticeSpecific to Advanced Therapy Medicinal Products (November 2017); ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
220. FDA Guidance For Industry: CGMP For Phase 1 Investigational Drugs (July 2008); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070273.pdf?utm_campaign=Google2%26;utm_source=fdaSearch%26;utm_medium=website%26;utm_term=cgmpphase1guidance%26;utm_content=1
221. European Commission – EudraLex the Rules Governing Medicinal Products in the EuropeanUnion, Volume 4, Detailed Commission Guidelines on Good Manufacturing Practice forInvestigational Medicinal Products for Human Use, Pursuint to the Second Subparagraph ofArticle 63(1) of Regulation (EU) No 536/2014 (December 2017); ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guideline_adopted_1_en_act_part1_v3.pdf
222. ICH The Common Technical Document For the Registration of Pharmaceuticals ForHuman Use: Quality – M4Q(R1): Quality Overall Summary of Module 2, Module 3 Quality(September 2002); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R1_Quality/M4Q__R1_.pdf
223. FDA Guidance For Industry: For the Submission of Chemistry, Manufacturing, and ControlsInformation for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibodyfor In Vivo Use (August 1996); www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/general/ucm173477.pdf
224. FDA Recalls, Market Withdrawals, & Safety Alerts – Enforcement Reports: EnforcementReport for Week of June 25, 2014 – Drugs – TEV-TROPIN [Somatropin, rDNA origin]; www.fda.gov/Safety/Recalls/EnforcementReports/default.htm
225. FDA Establishment Inspection Report: Celltrion Inc (June 2, 2017); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM603271.pdf
226. FDA Inspections, Compliance, Enforcement, and Criminal Investigations – Warning Letters:Celltrion Inc. (January 26, 2018); www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm594395.htm
227. FDA CDER Freedom of Information Act (FOIA) Electronic Reading Room: Celltrion FDA Form 483(July 9–17, 2018); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM615956.pdf
228. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
229. ICH Q11 Development and Manufacture of Drug Substances (Chemical Entities andBiotechnological/Biological Entities) (May 2012); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf
230. ICH Q3C(R5) Impurities: Guideline for Residual Solvents (February 2011); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf
231. ICH Q3D Guideline for Elemental Impurities (December 2014); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3D/Q3D_Step_4.pdf
232. Code of Federal Regulations (CFR) – Title 21 Food and Drugs: Part 610.15(b) ConstituentMaterials – Extraneous Protein; www.ecfr.gov/cgi-bin/text-idx?SID=870055794fb542c693cd7dddc011c4e0&mc=true&node=pt21.7.610&rgn=div5#se21.7.610_115
233. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Imlygic (Talimogene Laherparepvec) – Package Insert (October 2015); wayback.archive-it.org/7993/20170112213642/http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf
234. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Luxturna (Voretigene Neparvovec-rzyl) – Package Insert (December 2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM589541.pdf
235. EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy MedicinalProducts (March 22, 2018); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252056.pdf
236. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Lucentis (Ranibizumab):Approval History, Letters, Reviews and Related Documents – Package Insert (April 2017);www.accessdata.fda.gov/drugsatfda_docs/label/2017/125156s114lbl.pdf
237. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Perjeta (Pertuzumab):Approval History, Letters, Reviews and Related Documents – Package Insert (December2017); www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf
238. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Lumoxiti (MoxetumomabPasudotox-tdfk): Approval History, Letters, Reviews and Related Documents –Package Insert (September 2018); https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761104s000lbl.pdf
239. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Yescarta (Axicabtagene Ciloleucel) – Package Insert (2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581226.pdf
240. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Palynziq (Pegvaliase-pqpz):Approval History, Letters, Reviews and Related Documents – FDA Approval Letter(May 24, 2018); www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761079Orig1s000ltr.pdf
241. Li, K., Rogers, G., et.al., Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products; PDA J Pharm Sci and Tech (2015), 69: 590–619; PDA website, www.PDA.org
242. EMA Guideline on the Requirements for Quality Documentation Concerning BiologicalInvestigational Medicinal Products in Clinical Trials (September 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-requirements-quality-documentation-concerningbiological-investigational-medicinal_en-0.pdf
243. ICH M4Q(R1): Quality Overall Summary of Module 2, Module 3 Quality (September 2002);www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R1_Quality/M4Q__R1_.pdf
244. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Tremfya (Guselkumab):Approval History, Letters, Reviews and Related Documents – FDA BLA Approval Letter (July13, 2017); www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761061Orig1s000ltr.pdf
245. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Mepsevii (VestronidaseAlfa-vjbk): Approval History, Letters, Reviews and Related Documents – FDA BLA ApprovalLetter (November 15, 2017); www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761047Orig1s000ltr.pdf
246. FDA Guidance for Industry: CGMP For Phase 1 Investigational Drugs (July 2008); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM
247. pdf
248. Qiu, J., Li, K., et. al., Risk-Based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses; PDA J Pharm Sciand Tech (2015), 69: 334–345; journal.pda.org/content/69/3/33e4
249. FDA Guidance for Industry: For the Submission of Chemistry, Manufacturing, and ControlsInformation for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibodyfor In Vivo Use (August 1996); www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/general/ucm173477.pdf
250. EMA Guideline on Quality, Non-Clinical and Clinical Aspects of Medicinal ProductsContaining Genetically Modified Cells (July 2018); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252709.pdf
251. EMA Guideline on Human Cell-Based Medicinal Products (May 2008); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003894.pdf
252. FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of aTherapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/drugs/guidances/ucm291134.pdf
253. EMA Draft Guideline on Similar Biological Medicinal Products Containing Biotechology-DerivedProteins as Active Substance – Quality Issues (Revision 1) (May 2012); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf
254. FDA Advisory Committee Meetings – Meeting of the Arthritis Advisory Committee: SandozErlezi (Etanercept, Biosimilar Enbrel) – FDA Advisory Committee Briefing DocumentPrepared by the FDA (July 13, 2016); www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM510493.pdf
255. EMA European Public Assessment Report (EPAR): Herzuma (Trastuzumab, HerceptinBiosimilar) (December 2017); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002575/WC500249108.pdf
256. Donald Rumsfeld, U.S. Secretary of Defense, Press Conference at NATO Headquarters (June02, 2002); www.nato.int/docu/speech/2002/s020606g.htm
257. ICH Q6B Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
258. Kozlowski, S., and Swann P., Current and Future Issues in the Manufacturing and Development of Monoclonal Antibodies; Adv. Drug Deliv Rev. (2006) 58(5–6): 707–722
259. FDA Guidance for Industry: CGMP For Phase 1 Investigational Drugs (July 2008); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070273.pdf
260. EMA Guideline on the Requirements For Quality Documentation Concerning BiologicalInvestigational Medicinal Products in Clinical Trials (September 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-requirements-quality-documentation-concerningbiological-investigational-medicinal_en-0.pdf
261. ICH M4Q(R1): Quality Overall Summary of Module 2, Module 3: Quality (September 2002);www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R1_Quality/M4Q__R1_.pdf
262. EMA Guideline on Development, Production, Characterization, and Specification forMonoclonal Antibodies and Related Products (July 2016): www.ema.europa.eu/documents/scientific-guideline/guideline-development-production-characterisation-specification-monoclonal-antibodies-related_en.pdf
263. EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy MedicinalProducts (March 22, 2018); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252056.pdf
264. FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of aTherapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/drugs/guidances/ucm291134.pdf
265. EMA European Public Assessment Report (EPAR): Qarziba (Dinutuximab Beta Apeiron)(March 2017); www.ema.europa.eu/documents/assessment-report/dinutuximab-beta-apeironepar-public-assessment-report_en.pdf
266. EMA European Public Assessment Report (EPAR): Oxervate (Cenegermin, RecombinantNerve Growth Factor) (May 2017); www.ema.europa.eu/documents/assessment-report/oxervate-epar-public-assessment-report_en.pdf
267. Code of Federal Regulations Title 21 Food and Drugs: Part 211 – Definitions; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=211
268. EC Directive 2001/83/EC of the European Parliament and Council, Concerning CommunityCode Relating to Medicinal Products For Human Use; ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_cons2009/2001_83_cons2009_en.pdf
269. Code of Federal Regulations Title 21 Food and Drugs: Part 210.3 – Definitions; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=210.3
270. Code of Federal Regulations Title 21 Food and Drugs: Part 600.3 – Definitions; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=600.3
271. Code of Federal Regulations Title 21 Food and Drugs: Part 610.10 – Potency; www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=610.10
272. ICH Q6B Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
273. EMA Guideline on Potency Testing of Cell Based Immunotherapy Medicinal Products forthe Treatment of Cancer (July 2016); www.ema.europa.eu/documents/scientific-guideline/guideline-potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancerrevision-1_en.pdf
274. EMA Guideline on Development, Production, Characterisation and Specification forMonoclonal Antibodies and Related Products (July 2016); www.ema.europa.eu/documents/scientific-guideline/guideline-development-production-characterisation-specification-monoclonal-antibodies-related_en.pdf
275. FDA Drugs– Search Drugs@FDA – FDA Approved Drug Products: Crysvita (Burosumab-twza):Approval History, Letters, Reviews and Related Documents – Administrative andCorrespondence Documents – Mid-Cycle Communication Meeting (November 30, 2017);www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761068Orig1s000Admincones.pdf
276. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Crysvita (Burosumab-twza):FDA Market Approval Letter (April 17, 2018); www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761068Orig1s000Approv.pdf
277. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Oxervate (Cenegermin-bkbj):Approval History, Letters, Reviews and Related Documents – CMC Review –Executive Summary (August 07, 2018); www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761094Orig1s000ChemR.pdf
278. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Oxervate (Cenegermin-bkbj):FDA Market Approval Letter (August 22, 2018); www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761094Orig1s000Ltr.pdf
279. EMA European Withdrawal Assessment Report (EPAR): Fulphia (Pegfilgrastim, Biosimilarof Neulasta) (October 2016); www.ema.europa.eu/documents/withdrawal-report/withdrawal-assessment-report-fulphila_en.pdf
280. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Ocrevus(Ocrelizumab): Approval History, Letters, Reviews and Related Documents – CMCReview – Executive Summary (March 20, 2017); www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000ChemR.pdf
281. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Ocrevus (Ocrelizumab):FDA Market Approval Letter (April 28, 2017); www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761053Orig1s000ltr.pdf
282. Product-specific package inserts published on FDA website: CDER, FDA Drugs – SearchDrugs@FDA – FDA Approved Drug Products: FDA Package Insert, www.fda.gov/Drugs/default.htm; CBER, Biological Products & Establishments – Licensed Biological Productswith Supporting Documents: FDA Package Insert, www.fda.gov/BiologicsBloodVaccines/default.htm
283. Langille, S. E., Particulate Matter in Injectable Drug Products; PDA J Pharm Sci and Tech(2013), 67: 186–200; PDA website, www.PDA.org
284. Mathonet, S., Mahler, H-C., et.al., Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products; PDA J Pharm Sci andTech (2016), 70: 392–408; PDA website, www.PDA.org
285. ICH Q6A Specifications: Test Procedures and Acceptance Criteria For New Drug Substancesand New Drug Products: Chemical Substances (October 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6A/Step4/Q6Astep4.pdf
286. ICH Q6B Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
287. EMA Guideline on Development, Production, Characterisation and Specification forMonoclonal Antibodies and Related Products (July 2016); www.ema.europa.eu/documents/scientific-guideline/guideline-development-production-characterisation-specification-monoclonal-antibodies-related_en.pdf
288. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Nucala (Mepolizumab):Approval History, Letters, Reviews and Related Documents – Chemistry Reviews – OPQCMC Review Data Sheet (July 10, 2015); www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125526Orig1s000ChemR.pdf
289. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Amjevita (Adalimumab-atto):Approval History, Letters, Reviews and Related Documents – Other Reviews –CDRH Consult (September 22, 2016); www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000OtherR.pdf
290. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Aimovig (Erenumab-aooe):Approval History, Letters, Reviews and Related Documents – Other Reviews –CDRH Consult (January 02, 2018); www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761077Orig1s000OtherR.pdf
291. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Luxturna (Voretigene Neparvovec-rzyl) – Chemistry Review – DCGT CMC Review Data Sheet(December 08, 2017); www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm589507.htm
292. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data –Yescarta (Axicabtagene Ciloleucel) – Chemistry Review – DCGT CMC Review Data Sheet(November 29, 2017); www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm
293. ICH Q5C Stability Testing of Biotechnological/Biological Products (November 1995); www. ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_ Guideline.pdf
294. EMA Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products (March 2018); www.ema.europa.eu/documents/scientific-guideline/ guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf
295. EMA Guideline on the Quality, Non-clinical and Clinical Aspects of Medicinal Products Containing Genetically Modified Cells (July 2018); www.ema.europa.eu/documents/scientific- guideline/draft-guideline-quality-non-clinical-clinical-aspects-medicinal-products-containing- genetically_en.pdf
296. EMA Guideline on Human Cell-Based Medicinal Products (May 2008); www.ema.europa.eu/ documents/scientific-guideline/guideline-human-cell-based-medicinal-products_en.pdf
297. EMA Guideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials (September 2018); www.ema.europa.eu/ documents/scientific-guideline/guideline-requirements-quality-documentation-concerningbiological- investigational-medicinal_en-0.pdf
298. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Palynziq (Pegvaliase-pqpz): Approval History, Letters, Reviews and Related Documents – FDA Market Approval Letter (May 24, 2018); www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761079Orig 1s000ltr.pdf
299. Zeiss, B., Tungsten in the Production of Prefillable Syringes – Also Possible Without Tungsten; IPI (2017), 9(3): 126–130; ipimediaworld.com/wp-content/uploads/2017/10/Tungsten-in-theproduction- 1.pdf
300. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Ocrevus (Ocrelizumab): Approval History, Letters, Reviews and Related Documents – Administrative and Correspondence Documents – FDA Type C CMC-Focused Meeting Minutes (February 29, 2016); www.accessdata. fda.gov/drugsatfda_docs/nda/2017/761053Orig1s000AdminCorres.pdf
301. ICH Q8 (R2) Pharmaceutical Development (August 2009); www.ich.org/fileadmin/Public_ Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf
302. ICH Q11 Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) (May 2012); www.ich.org/fileadmin/Public_Web_Site/ ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf
303. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/ Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
304. European Commission (EC) Guidelines on Good Manufacturing Practices for Investigational Medicinal Products for Human Use (December 08, 2017); ec.europa.eu/health/sites/health/ files/files/eudralex/vol-10/guideline_adopted_1_en_act_part1_v3.pdf
305. European Commission (EC) Guidelines on Good Manufacturing Practices Specific to Advanced Therapy Medicinal Products (November 22, 2017); ec.europa.eu/health/sites/ health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf
306. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Imfinzi (Durvalumab): Approval History, Letters, Reviews and Related Documents – Administrative and Correspondence Documents – Information Request Letter (December 20, 2016); www.accessdata. fda.gov/drugsatfda_docs/nda/2017/761069Orig1s000AdminCorres.pdf
307. FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Kymriah (Tisagenlecleucel) – Approval History, Letters, Reviews and Related Documents – Mid-Cycle Commuication Summary (May 18, 2017); www.fda.gov/BiologicsBloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/ucm573706.htm
308. ICH Q6A Specifications: Test Procedures and Acceptance Criteria For New Drug Substances and New Drug Products: Chemical Substances (October 1999); www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q6A/Step4/Q6Astep4.pdf
309. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Zinplava (Bezlotoxumab): Approval History, Letters, Reviews and Related Documents – FDA Market Approval Letter (October 21, 2016); www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/761046Orig1s0 00ltr.pdf
310. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Mepsevii (Vestronidase Alfa-vjbk): Approval History, Letters, Reviews and Related Documents – FDA Market Approval Letter (November 15, 2017); www.accessdata.fda.gov/drugsatfda_docs/appletter/2 017/761047Orig1s000ltr.pdf
311. EMA European Public Assessment Report (EPAR): Kanuma (Sebelipase Alfa) (June 2015); www.ema.europa.eu/documents/assessment-report/kanuma-epar-public-assessmentreport_ en.pdf
312. FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/ drugs/guidances/ucm291134.pdf
313. EMA Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues (Revision 1) (May 2014); www.ema.europa.eu/ documents/scientific-guideline/guideline-similar-biological-medicinal-products-containingbiotechnology- derived-proteins-active_en-0.pdf
314. World Health Organization (WHO) Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) (October 2009); www.who.int/biologicals/areas/biological_therapeutics/ BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
315. FDA Advisory Committee Meetings – Meeting of the Arthritis Advisory Committee: Amgen ABP-501 (Adalimumab, Biosimilar to Humira) – FDA Advisory Committee Briefing Document Prepared by the FDA (July 12, 2016); www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM510293.pdf
316. Aptevo Therapeutics webpage – Investors – Financial Reports: United States Securies and Exchange Commission (SEC) Form 10-Q for the Quarterly Period Ended September 30, 2016; ir.aptevotherapeutics.com/static-files/506443c3-3e2b-498d-9646-78e582b5ccf8
317. Aptevo Therapeutics webpage – News – March 15, 2017 – Aptevo Therapeutics Announces New IXINITY Supply Available May 2017; ir.aptevotherapeutics.com/news-releases/ news-release-details/aptevo-therapeutics-announces-new-ixinity-supply-available-may
318. Motley Fool Transcript of Novartis Second-Quarter (Q2) Earnings Report (July 18, 2018); www.fool.com/earnings/call-transcripts/2018/07/18/novartis-ag-nvs-q2-2018-earnings-conference- call-t.aspx
319. EMA European Public Assessment Report (EPAR): Shingrix (Herpes Zoster Vaccine, Recombinant, Adjuvanted) (January 2018); www.ema.europa.eu/documents/ assessment-report/shingrix-epar-public-assessment-report_en.pdf
320. EMA European Public Assessment Report (EPAR): Ilumetri (Tildrakizumab) (July 2018); www. ema.europa.eu/documents/assessment-report/ilumetri-epar-public-assessment-report_en.pdf
321. EMA European Public Assessment Report (EPAR): Bavencio (Avelumab) (July 2017); www. ema.europa.eu/documents/assessment-report/bavencio-epar-public-assessment-report_en.pdf
322. Vezer, B., Buzas, Z., et.al., Authorized Manufacturing Changes for Therapeutic Monoclonal Antibodies (mAbs) in European Public Assessment Report (EPAR) Documents; Curr Med Res Opin(2016), 32: 829–834
323. Tebbey, P. W., Varga, A., et.al., Consistency of Quality Attributes for the Glycosylated Monoclonal Antibody Humira® (Adalimumab); MAbs(2015), 805–811
324. ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process (November 2004); www.ich.org/fileadmin/Public_Web_Site/ICH_ Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf
325. EMA Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products (March 2018); www.ema.europa.eu/documents/scientific-guideline/ guideline-quality-non-clinical-clinical-aspects-gene-therapy-medicinal-products_en.pdf
326. EMA Guideline on the Quality, Non-clinical and Clinical Aspects of Medicinal Products Containing Genetically Modified Cells (July 2018); www.ema.europa.eu/documents/scientific- guideline/draft-guideline-quality-non-clinical-clinical-aspects-medicinal-products-containing- genetically_en.pdf
327. FDA (Draft) Guidance for Industry: Comparability Protocols for Human Drugs and Biologics – Chemistry, Manufacturing and Controls Information (April 2016); www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM496611.pdf
328. FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/ drugs/guidances/ucm291134.pdf
329. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Amjevita (Adalimumab-atto, Biosimilar of Humira): Approval History, Letters, Reviews and Related Documents – Chemistry Review(s) – OBP CMC Review Data Sheet (August 15, 2016); www.accessdata. fda.gov/drugsatfda_docs/nda/2016/761024Orig1s000ChemR.pdf
330. EMA Reflection Paper on Statistical methodology for the Comparative Assessment of Quality Attributes in Drug Development (March 2017); www.ema.europa.eu/documents/scientificguideline/ draft-reflection-paper-statistical-methodology-comparative-assessment-qualityattributes- drug_en.pdf
331. EMA European Public Assessment Report (EPAR): Mvasi (Bevacizumab, Biosimilar of Avastin) (January 2018); www.ema.europa.eu/documents/assessment-report/mvasi-eparpublic- assessment-report_en.pdf
332. Code of Federal Regulations Title 21 Food and Drugs – Part 312.47 Meetings; www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.47
333. FDA Guidance For Industry: IND Meetings For Human Drugs and Biologics – Chemistry, Manufacturing, and Controls Information (May 2001); www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070568.pdf
334. EMA Annual Report 2017 (May 2018); https://www.ema.europa.eu/documents/annualreport/ 2017-annual-report-european-medicines-agency_en.pdf
335. FDA Guidance for Industry and Review Staff – Good Review Practice: Best Practices for Communication Between IND Sponsors and FDA During Drug Development (December 2017); www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm475586.pdf
336. FDA (Draft) Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (December 2017); www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM590547.pdf
337. FDA (Draft) Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products (June 2018); www.fda.gov/downloads/Drugs/Guidance- ComplianceRegulatoryInformation/Guidances/UCM609662.pdf
338. Yetter, R., FDA PDUFA Activities in Drug Development; www.fda.gov/downloads/ForIndustry/ UserFees/PrescriptionDrugUserFee/UCM207568.pdf
339. FDA CDER 21st Century Review Process: Desk Reference Guide NDA/BLA Review Process; www.fda.gov/downloads/aboutfda/centersoffices/cder/manualofpoliciesprocedures/ ucm218757.pdf
340. FDA FY2017 Performance Report to Congress for the Prescription Drug User Fee Act (PDUFA); www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/ UserFeeReports/PerformanceReports/UCM606719.pdf
341. EMA Scientific Advice and Protocol Assistance webpage; www.ema.europa.eu/en/ human-regulatory/research-development/scientific-advice-protocol-assistance
342. EMA Guidance for Applicants Seeking Scientific Advice and Protocol Assistance (June 2017); www.ema.europa.eu/documents/regulatory-procedural-guideline/european-medicinesagency- guidance-applicants-seeking-scientific-advice-protocol-assistance_en.pdf
343. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Trogarzo (Ibalizumab-uiyk): Approval History, Letters, Reviews and Related Documents – Administration and Correspondence Documents – CMC-Focused Pre-BLA Meeting Minutes (September 04, 2015); www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761065Orig1s000AdminCorres. pdf
344. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Kevzara (Sarilumab): Approval History, Letters, Reviews and Related Documents – Administration and Correspondence Documents – CMC-Focused Pre-BLA Meeting Minutes (December 16, 2014); www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761037Orig1s000Admincorres. pdf
345. FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Crysvita (Burosumab-twza): Approval History, Letters, Reviews and Related Documents – Administration and Correspondence Documents – Pre-BLA Meeting Minutes (June 19, 2017);www.accessdata. fda.gov/drugsatfda_docs/nda/2018/761068Orig1s000Admincorres.pdf
346. EMA European Public Withdrawal Assessment Report (EPAR): Theraloc (Nimotuzumab) (May 2009);www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_ assessment_report/2010/01/WC500063198.pdf
347. EMA European Public Assessment Report (EPAR): Oxervate (Cenegermin, Recombinant Nerve Growth Factor) (May 2017); www.ema.europa.eu/documents/assessment-report/ oxervate-epar-public-assessment-report_en.pdf